TCM and conventional drug
Phase 3Small molecule
TCM and conventional drug is one of 65 small molecule programs targeting Pneumonia. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
TCM and conventional drug
HHenan University of Traditional Chinese Medicine
Phase 3
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia1 trial
Outcome1 trial
Immune Function1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCM and conventional drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details